High serum sclerostin levels are associated with a better outcome in haemodialysis patients

[en] Sclerostin is an osteocyte hormone that de- creases osteoblastogenesis. Sclerostin may play a key role in osteoporosis and also in vascular calcification (VC). In chron- ic kidney disease and haemodialysis (HD) patients, serum sclerostin levels are high. Aim: To assess the correlation of serum sclerostin levels with VC, bone mineral density (BMD), and survival rate in HD patients. Methods: A cross-sectional study was conducted in prevalent HD patients to correlate serum sclerostin tertiles with the Kauppila aortic calcification score, BMD scores and survival rate. Results: We studied 207 patients who had a mean serum sclerostin level of 1.9 ± 0.7 ng/ml. Compared to patients in the 1st tertile of serum sclerostin levels (0.6–1.53 ng/ml), patients in the 3rd tertile (2.2–4.6 ng/ml) were significantly older (73.7 ± 12 vs. 64.7 ± 18 years), more frequently of the male gender (74 vs. 48%), had lower serum bone-specific alkaline phosphatases values (14 ± 9 vs. 20.4 ± 13 µg/l), were less frequently treated with alfacalcidol, displayed lower aortic calcification scores (9.5 ± 5 vs. 12.5 ± 7/24) and had higher BMD scores. Furthermore, patients of the 3rd tertile displayed a lower mortality rate compared to tertile 1 using multivariable adjusted Cox mod- el (hazard ratio 0.5, 95% CI 0.25–0.93, p = 0.03). The main fac- tors associated with VC score were age, diabetes, cardiovas- cular disease, CRP level and Warfarin use. Conclusion: Our study of HD patients shows that higher serum sclerostin lev- els are associated with higher BMD, lower aortic calcification scores, and a better survival rate.

Disciplines :

Laboratory medicine & medical technology

Author, co-author :

Jean, Guillaume

Chazot, Charles

Bresson, Eric

Zaoui, Eric

CAVALIER, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique

Language :

English

Title :

High serum sclerostin levels are associated with a better outcome in haemodialysis patients

Publication date :

2016

Journal title :

Nephron. Clinical Practice

eISSN :

1660-2110

Publisher :

S. Karger, Basel, Switzerland

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 June 2016

Statistics

Number of views

63 (3 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD). Kidney Int Suppl 2009; 113:S1-S130.
Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, Shoji S, Okuno S, Kim M, Miki T, Morii H: Serum levels of 1,25-Dihydroxyvitamin D, 24,25-Dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999; 55: 1019-1027.
Gutierrez OM: Fibroblast growth factor 23, Klotho, and disordered mineral metabolism in chronic kidney disease: unraveling the intricate tapestry of events and implications for therapy. J Ren Nutr 2013; 23: 250-254.
Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M: Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 1996; 11: 970-976.
Toussaint ND, Elder GJ, Kerr PG: A rational guide to reducing fracture risk in dialysis patients. Semin Dial 2010; 23: 43-54.
Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: 1345-1354.
Hofbauer LC, Brueck CC, Shanahan CM, Schoppet M, Dobnig H: Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259.
Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE: Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010; 95: 2248-2253.
Sigrist MK, Levin A, Er L, McIntyre CW: Elevated osteoprotegerin is associated with allcause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant 2009; 24: 3157-3162.
Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796.
Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K: Outcome predictability of serum alkaline phosphatase in men with pre-Dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011.
Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM; NECOSAD Study Group: High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288-293.
Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D'Haese PC: Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 2013; 28: 3024-3030.
Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH: Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/ sclerostin. J Biol Chem 2008; 283: 5866-5875.
Ott SM: Sclerostin and Wnt signaling-the pathway to bone strength. J Clin Endocrinol Metab 2005; 90: 6741-6743.
Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G: Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480.
Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH: Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882.
Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M: Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230.
Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE: The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS One 2011; 6:e19595.
Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M: Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 2013; 14: 219.
Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, Cristol JP: Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015;30: 1345-1356.
Claes KJ, Viaene L, Heye S, Meijers B, D'Haese P, Evenepoel P: Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 2013; 98: 3221-3228.
Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM: Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005; 15: 928-935.
Honkanen E, Kauppila L, Wikstrom B, Rensma PL, Krzesinski JM, Aasarod K, Verbeke F, Jensen PB, Mattelaer P, Volck B; CORD Study Group: Abdominal aortic calcification in dialysis patients: results of the cord study. Nephrol Dial Transplant 2008; 23: 4009-4015.
Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D: The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823.
Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M: Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248-255.
Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, Hamann C, Hofbauer LC: Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res 2013; 28: 1760-1770.
Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD: Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013; 24: 489-494.
Gregson CL, Poole KE, McCloskey EV, Duncan EL, Rittweger J, Fraser WD, Smith GD, Tobias JH: Elevated circulating sclerostin concentrations in individuals with high bone mass, with and without LRP5 mutations. J Clin Endocrinol Metab 2014; 99: 2897-2907.
Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY: Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013; 56: 355-362.
Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA: High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res 2012; 27: 2592-2602.
Arasu A, Cawthon PM, Lui LY, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR Study of Osteoporotic Fractures Research Group: Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 2012; 97: 2027-2032.
Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC: Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 2014; 9: 1254-1262.
Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146: 4577-4583.
Amrein K, Dobnig H, Wagner D, Piswanger-Solkner C, Pieber TR, Pilz S, Tomaschitz A, Dimai HP, Fahrleitner-Pammer A: Sclerostin in institutionalized elderly women: associations with quantitative bone ultrasound, bone turnover, fractures, and mortality. J Am Geriatr Soc 2014; 62: 1023-1029.
Moyses RM, Jamal SA, Graciolli FG, dos Reis LM, Elias RM: Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol 2015; 47: 847-850.
Ritz E, Stefanski A, Rambausek M: The role of the parathyroid glands in the uremic syndrome. Am J Kidney Dis 1995; 26: 808-813.
Asamiya Y, Yajima A, Shimizu S, Otsubo S, Tsuchiya K, Nitta K: Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level. Osteoporos Int 2015; 26: 1017-1028.
Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T: PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299:F882-F889.
Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA; European Uremic Toxin (EUTox) Work Group: Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther 2014; 10: 463-470.
Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnen-Dechent W, Knuchel R, Floege J, Schneider RK: Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 2013; 28: 856-868.
Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S: Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 2014; 59: 1-6.
Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Bruyere O, Reginster JY, Pottel H, Cavalier E: Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 2014; 128: 127-134.
Goncalves FL, Elias RM, Dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moyses RM: Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 2014; 15: 190.